XML 50 R32.htm IDEA: XBRL DOCUMENT v3.19.1

Revenues (Tables)

12 Months Ended

Dec. 31, 2018

Revenues [Abstract]

Schedule of net product revenues by product

The Company’s net product revenues consisted of the following for the years ended December 31:

						2018						2017						2016
Products:
Acetadote						$	4,284,111					$	6,576,720					$	7,214,341
Omeclamox-Pak						623,297						1,761,868						2,536,027
Kristalose						12,055,625						11,455,805						15,898,760
Vaprisol						1,763,874						1,576,222						1,857,838
Caldolor						5,001,997						4,178,443						4,132,833
Ethyol						10,545,906						10,835,038						838,386
Totect						850,965						3,992,467						—
Vibativ						5,075,057						—						—
Total net product revenues						$	40,200,832					$	40,376,563					$	32,478,185

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration